Telomerase activity in plasma cell dyscrasias

被引:0
|
作者
D Xu
C Zheng
S Bergenbrant
G Holm
M Björkholm
Q Yi
A Gruber
机构
[1] Karolinska Hospital,Department of Medicine, Division of Hematology
[2] University of Arkansas for Medical Sciences,Myeloma and Transplantation Research Center
来源
British Journal of Cancer | 2001年 / 84卷
关键词
hTERT; multiple myeloma; plasma cells; telomerase;
D O I
暂无
中图分类号
学科分类号
摘要
Activation of telomerase is essential for in vitro cellular immortalization and tumorigenesis. In the present study, we investigated telomerase activation and its implications in plasma cell dyscrasias including monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and plasma cell leukaemia (PCL). All 5 patients with MGUS exhibited normal levels of telomerase activity in their plasma cells. Elevated telomerase activity was found in the samples from 21/27 patients with MM and 4/4 with PCL. In addition, 4 myeloma cell lines all expressed high levels of telomerase activity. The expression of telomerase reverse transcriptase (hTERT) and telomerase RNA template (hTER) was positively associated with the levels of telomerase activity in MM/PCL. Tankyrase expression was upregulated, concomitant with the induction of hTERT and activation of telomerase in MM/PCL. The present findings indicate that MGUS cells may not be immortalized and that activation of telomerase plays a role in the malignant transformation from MGUS to MM. © 2001 Cancer Research Campaign
引用
收藏
页码:621 / 625
页数:4
相关论文
共 50 条
  • [1] Telomerase activity in plasma cell dyscrasias
    Xu, D
    Zheng, C
    Bergenbrant, S
    Holm, G
    Björkholm, M
    Yi, Q
    Gruber, A
    BRITISH JOURNAL OF CANCER, 2001, 84 (05) : 621 - 625
  • [2] Treatment of plasma cell dyscrasias with lenalidomide
    Dimopoulos, M. A.
    Kastritis, E.
    Rajkumar, S. V.
    LEUKEMIA, 2008, 22 (07) : 1343 - 1353
  • [3] Ocular complications of plasma cell dyscrasias
    Singh, Rohan Bir
    Singhal, Sachi
    Sinha, Shruti
    Cho, Junsang
    Nguyen, Anne Xuan-Lan
    Dhingra, Lovedeep Singh
    Kaur, Snimarjot
    Sharma, Vasudha
    Agarwal, Aniruddha
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2023, 33 (05) : 1786 - 1800
  • [4] Skeletal changes in plasma cell dyscrasias
    Weber, Tim Frederik
    Mokry, Theresa
    RADIOLOGE, 2021, 61 (12): : 1078 - 1089
  • [5] POSTTRANSPLANTATION PLASMA-CELL DYSCRASIAS
    JOSEPH, G
    BARKER, RL
    YUAN, B
    MARTIN, A
    MEDEIROS, J
    PEIPER, SC
    CANCER, 1994, 74 (07) : 1959 - 1964
  • [6] Treatment of plasma cell dyscrasias with lenalidomide
    M A Dimopoulos
    E Kastritis
    S V Rajkumar
    Leukemia, 2008, 22 : 1343 - 1353
  • [7] The promise and harms of screening for plasma cell dyscrasias
    Mohyuddin, Ghulam Rehman
    Chakraborty, Rajshekhar
    Scheffer Cliff, Edward R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (06) : 704 - 707
  • [8] Whole blood viscosity in plasma cell dyscrasias
    Uggla, Bertil
    Nilsson, Torbjorn K.
    CLINICAL BIOCHEMISTRY, 2015, 48 (03) : 122 - 124
  • [9] Diagnosis and management of neuropathies associated with plasma cell dyscrasias
    Rosenbaum, Evan
    Marks, Douglas
    Raza, Shahzad
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 3 - 14
  • [10] Vitamin D and plasma cell dyscrasias: reviewing the significance
    Nicholas Burwick
    Annals of Hematology, 2017, 96 : 1271 - 1277